Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
gptkb:drug |
| gptkbp:administeredBy |
oral
intramuscular injection |
| gptkbp:ATCCode |
J04AC01
|
| gptkbp:brand |
gptkb:Laniazid
gptkb:Nydrazid |
| gptkbp:CASNumber |
54-85-3
|
| gptkbp:chemicalFormula |
C6H7N3O
|
| gptkbp:contraindication |
acute liver disease
previous isoniazid-induced hepatitis |
| gptkbp:discoveredBy |
gptkb:Jörgen_Lehmann
|
| gptkbp:discoveredIn |
1951
|
| gptkbp:drugClass |
hydrazide
|
| gptkbp:eliminationHalfLife |
1–4 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
isoniazid
|
| gptkbp:introducedIn |
1952
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits mycolic acid synthesis
|
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
137.14 g/mol
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intramuscular |
| gptkbp:sideEffect |
fever
peripheral neuropathy rash hepatotoxicity |
| gptkbp:synonym |
isonicotinic acid hydrazide
|
| gptkbp:usedFor |
tuberculosis
|
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:rifampicin
|
| gptkbp:bfsLayer |
5
|